Operating as a life science company builder, DiNAQOR creates and scales focused biotechnology companies around differentiated technology platforms. Its portfolio includes DiNATEQ AG, advancing next-generation precision delivery technologies; DiNAMIQS, an adeno-associated virus (AAV) manufacturing and development platform spun out of DiNAQOR and subsequently scaled through a majority-stake transaction with Siegfried AG to establish a category-defining, end-to-end GMP viral therapeutics platform; and DiNABiOS, a leading human cell and tissue CDMO supporting pharmaceutical partners in R&D and translational development. Together, these ventures underscore DiNAQOR’s proven ability to originate, build, and strategically scale high-impact biotechnology platforms.